HUE052128T2 - Eljárás az 1-(5,6-diklór-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-karbonsav meglumin sója kristályainak elõállítására - Google Patents

Eljárás az 1-(5,6-diklór-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-karbonsav meglumin sója kristályainak elõállítására

Info

Publication number
HUE052128T2
HUE052128T2 HUE18191088A HUE18191088A HUE052128T2 HU E052128 T2 HUE052128 T2 HU E052128T2 HU E18191088 A HUE18191088 A HU E18191088A HU E18191088 A HUE18191088 A HU E18191088A HU E052128 T2 HUE052128 T2 HU E052128T2
Authority
HU
Hungary
Prior art keywords
imidazol
pyrazole
benzo
dichloro
carboxylic acid
Prior art date
Application number
HUE18191088A
Other languages
English (en)
Hungarian (hu)
Inventor
Kia Sepassi
Michele C Rizzolio
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HUE052128T2 publication Critical patent/HUE052128T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
HUE18191088A 2011-10-25 2012-10-25 Eljárás az 1-(5,6-diklór-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-karbonsav meglumin sója kristályainak elõállítására HUE052128T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161551395P 2011-10-25 2011-10-25

Publications (1)

Publication Number Publication Date
HUE052128T2 true HUE052128T2 (hu) 2021-04-28

Family

ID=47116519

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18191088A HUE052128T2 (hu) 2011-10-25 2012-10-25 Eljárás az 1-(5,6-diklór-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-karbonsav meglumin sója kristályainak elõállítására

Country Status (14)

Country Link
US (4) US9273034B2 (enExample)
EP (3) EP3461820B1 (enExample)
JP (2) JP6122862B2 (enExample)
KR (1) KR102087020B1 (enExample)
CN (2) CN104053439B (enExample)
AU (2) AU2012328763A1 (enExample)
BR (1) BR112014009910B1 (enExample)
CA (1) CA2853455C (enExample)
CY (1) CY1123426T1 (enExample)
ES (3) ES2818977T3 (enExample)
HU (1) HUE052128T2 (enExample)
IN (1) IN2014DN03155A (enExample)
MX (2) MX368157B (enExample)
WO (1) WO2013063221A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134750A1 (en) * 2008-04-28 2009-11-05 Janssen Pharmaceutica Nv Benzoimidazoles as prolyl hydroxylase inhibitors
WO2013040515A1 (en) 2011-09-14 2013-03-21 Neupharma, Inc. Certain chemical entities, compositions, and methods
HUE052128T2 (hu) * 2011-10-25 2021-04-28 Janssen Pharmaceutica Nv Eljárás az 1-(5,6-diklór-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-karbonsav meglumin sója kristályainak elõállítására
WO2013112950A2 (en) 2012-01-25 2013-08-01 Neupharma, Inc. Certain chemical entities, compositions, and methods
EP2897618B1 (en) 2012-09-24 2021-11-17 Neupharma, Inc. Certain chemical entities, compositions, and methods
EP2916838B1 (en) 2012-11-12 2019-03-13 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN104610153B (zh) * 2015-01-19 2017-02-22 沈阳中海生物技术开发有限公司 奥扎格雷葡甲胺盐及其组合物、制备方法和用途
MX2021001033A (es) 2018-08-07 2021-07-07 Metagone Biotech Inc Sales de amonio de 3-(3,5-dibromo-4-hidroxibencilideno)-5-indo-1,3 -dihidroindol-2-ona y sus usos.
BR112022010388A2 (pt) 2019-11-28 2022-10-25 Nihon Nohyaku Co Ltd Composto de benzimidazol ou sal deste, agente inseticida e acaricida agrícola e hortícola que contém o referido composto e método para sua utilização
US20230218592A1 (en) 2020-04-20 2023-07-13 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
WO2022251563A1 (en) 2021-05-27 2022-12-01 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
WO2025049599A1 (en) 2023-08-29 2025-03-06 President And Fellows Of Harvard College Methods for treating muscle-related disorders by modulating prolyl hydroxylase 3

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1207994B (it) * 1986-01-03 1989-06-01 Therapicon Srl Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche.
DE3783122T2 (de) 1986-10-22 1993-04-22 Schering Corp Verwendung von rekombiniertem menschlichem alpha-interferon zur herstellung eines arzneimittels zur behandlung des aids-virus.
DE3824658A1 (de) 1988-07-15 1990-01-18 Schering Ag N-hetaryl-imidazolderivate
US5258362A (en) 1991-06-11 1993-11-02 Abbott Laboratories Renin inhibiting compounds
ES2101420T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
JP3314938B2 (ja) 1995-06-06 2002-08-19 ファイザー・インコーポレーテッド グリコーゲンホスホリラーゼ抑制剤としての置換されたn−(インドール−2−カルボニル)−グリシンアミド類および誘導体
ATE253073T1 (de) 1997-03-07 2003-11-15 Metabasis Therapeutics Inc Neue benzimidazol inhibitoren der fructose-1,6- bisphosphatase
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
TR200002480T2 (tr) 1998-02-27 2000-12-21 Pfizer Products Inc. İzaşemi tedavisi için guanidin türevleri
ES2362727T3 (es) 1999-11-22 2011-07-12 Mallinckrodt Inc. Sensor de pulsioxímetro con una tira ensanchada.
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
DE602004031114D1 (de) 2003-06-06 2011-03-03 Fibrogen Inc Stickstoffhaltige heteroarylverbindungen und deren verwendungen zur erhoehung des gehaltes von endogenem erythropoietin
AU2004261610B2 (en) 2003-07-28 2010-05-20 Janssen Pharmaceutica N.V. Benzimidazole, benzthiazole and benzoxazole derivatives and their use as LTA4H modulators
KR20060105872A (ko) 2003-12-29 2006-10-11 반유 세이야꾸 가부시끼가이샤 신규한 2-헤테로아릴 치환된 벤즈이미다졸 유도체
ATE513833T1 (de) 2005-03-02 2011-07-15 Fibrogen Inc Thienopyridinverbindungen und verfahren zu ihrer verwendung
US20060276477A1 (en) 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
AU2006326662B2 (en) 2005-12-09 2011-07-28 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
CN101374815B (zh) 2006-01-27 2013-07-17 菲布罗根有限公司 使低氧诱导因子(hif)稳定的氰基异喹啉化合物
TW200808793A (en) 2006-03-07 2008-02-16 Smithkline Beecham Corp Prolyl hydroxylase inhibitors
US20090176825A1 (en) 2006-05-16 2009-07-09 Fitch Duke M Prolyl hydroxylase inhibitors
AR061570A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto
ATE485264T1 (de) 2006-06-26 2010-11-15 Warner Chilcott Co Llc Prolylhydroxylase-hemmer und verfahren zu ihrer anwendung
WO2008033739A2 (en) 2006-09-12 2008-03-20 Neurogen Corporation Benzimidazole carboxamide derivatives
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050513A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
JP5178738B2 (ja) 2006-12-20 2013-04-10 メルク・シャープ・アンド・ドーム・コーポレーション 新規なjnk阻害剤
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
AU2008241503A1 (en) 2007-04-18 2008-10-30 Merck Sharp & Dohme Corp. Novel 1,8-naphthyridine compounds
AU2008241483B2 (en) 2007-04-18 2011-03-24 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
CA2685219C (en) 2007-05-04 2012-06-19 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
US8030346B2 (en) 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
WO2009024190A1 (en) * 2007-08-22 2009-02-26 4Sc Ag Indolopyridines as inhibitors of the kinesin spindle protein (eg5 )
DE102007048447A1 (de) 2007-10-10 2009-04-16 Bayer Healthcare Ag Substituierte Dihydropyrazolthione und ihre Verwendung
DE102007049157A1 (de) 2007-10-13 2009-04-16 Bayer Healthcare Ag Substituierte Dihydrotriazolone und ihre Verwendung
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
WO2009086044A1 (en) 2007-12-19 2009-07-09 Smith Kline Beecham Corporation Prolyl hydroxylase inhibitors
US20110003013A1 (en) 2008-01-04 2011-01-06 Garvan Institute Of Medical Research Method of increasing metabolism
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
AU2009217543A1 (en) 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydro-1H-pyrrolo fused pyridones
AU2009217541A1 (en) 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydrothieno pyridines
US8471024B2 (en) 2008-02-25 2013-06-25 Merck Sharp & Dohme, Corp. Tetrahydrofuropyridones
ES2524883T3 (es) 2008-03-18 2014-12-15 Merck Sharp & Dohme Corp. 4-Hidroxipirimidina-5-carboxamidas sustituidas
WO2009134750A1 (en) * 2008-04-28 2009-11-05 Janssen Pharmaceutica Nv Benzoimidazoles as prolyl hydroxylase inhibitors
AU2010213814B2 (en) 2009-02-10 2015-07-30 Janssen Pharmaceutica Nv Quinazolinones as prolyl hydroxylase inhibitors
JP5755741B2 (ja) 2010-08-13 2015-07-29 ヤンセン ファーマシューティカ エヌ.ベー. プロリルヒドロキシラーゼインヒビタとしての4−アミノキナゾリン−2−イル−1−ピラゾール−4−カルボン酸化合物
HUE052128T2 (hu) * 2011-10-25 2021-04-28 Janssen Pharmaceutica Nv Eljárás az 1-(5,6-diklór-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-karbonsav meglumin sója kristályainak elõállítására

Also Published As

Publication number Publication date
KR20140094547A (ko) 2014-07-30
AU2017204598A1 (en) 2017-07-27
WO2013063221A1 (en) 2013-05-02
HK1202237A1 (zh) 2015-09-25
EP3461820B1 (en) 2020-07-29
CN104053439A (zh) 2014-09-17
ES2818977T3 (es) 2021-04-14
US9708298B2 (en) 2017-07-18
MX344109B (es) 2016-12-05
CA2853455A1 (en) 2013-05-02
KR102087020B1 (ko) 2020-03-11
JP2014530915A (ja) 2014-11-20
MX368157B (es) 2019-09-20
ES2574262T3 (es) 2016-06-16
ES2689481T3 (es) 2018-11-14
AU2017204598B2 (en) 2019-03-28
JP6122862B2 (ja) 2017-04-26
CN104053439B (zh) 2016-08-24
US20180201605A1 (en) 2018-07-19
US20160340338A1 (en) 2016-11-24
MX2014005075A (es) 2014-08-08
BR112014009910A2 (pt) 2017-04-25
BR112014009910B1 (pt) 2020-06-30
EP3461820A1 (en) 2019-04-03
EP2776023A1 (en) 2014-09-17
EP3091009A1 (en) 2016-11-09
IN2014DN03155A (enExample) 2015-05-22
CY1123426T1 (el) 2021-12-31
US20190152955A1 (en) 2019-05-23
US10807969B2 (en) 2020-10-20
US9273034B2 (en) 2016-03-01
EP3091009B1 (en) 2018-08-29
JP2017141270A (ja) 2017-08-17
CA2853455C (en) 2019-12-03
CN106038556A (zh) 2016-10-26
NZ624022A (en) 2015-05-29
US20140329873A1 (en) 2014-11-06
EP2776023B1 (en) 2016-03-09
AU2012328763A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
HUE052128T2 (hu) Eljárás az 1-(5,6-diklór-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-karbonsav meglumin sója kristályainak elõállítására
EP2439173A4 (en) METHOD FOR PRODUCING AN IMPEDICATIVE SALT
ZA201004848B (en) Method for the production of disubstituted imidazolium salts
AP2013007252A0 (en) Heterocyclic compounds as kinase inhibitors
IL223813A0 (en) Process for preparation of optically active diamine derivative salt
IL258704B (en) History of hydantoins used as kv3 inhibitors
EP2755955A4 (en) METHOD FOR PRODUCING SUBSTITUTED 3'-HYDRAZIN BIPHENYL-3-CARBOXYLIC ACID COMPOUNDS
IL220211A (en) Process for Preparation of Acid History 1 - (Alkyl / Phenyl / Pyrid-2-Il) -5-Carboxylic Pyrazole and Intermediates Obtained in This Process
PL2819997T3 (pl) Sposób otrzymywania N-metoksy-[1-metylo-2-fenyloetylo]amidów kwasu 3-difluoro-metylo-1-metylo-1H-pirazolo-4-karboksylowego podstawionych grupą fenylową
ZA201206084B (en) Method for preparing tetrazole methanesulfonic acid salts,and novel compound used in same
SI2635563T1 (sl) Kristaliniäśne oblike hidrokloridne soli (4a-r,9a-s)-1-(1h-benzoimidazol -5-karbonil)-2,3,4,4a,9,9a-heksahidro-1h-indeno(2,1-b)piridin-6- karbonitrila in njihove uporabe kot inhibitorji hsd
ZA201200821B (en) Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
EG26957A (en) Process for the preparation of pyrazole carboxylicacid amides
EP2289875A4 (en) PROCESS FOR PRODUCING PERFLUOROALCANESULFINIC ACID SALT
IL207431A0 (en) New process for the preparation of cyclohexanecarboxylic acid derivatives
PL2443082T3 (pl) Sposób wytwarzania kryształów kwasu adypinowego
IL227317A0 (en) A process for the preparation of pyrazole carboxylic acid amide
EP2687515A4 (en) PROCESS FOR PREPARING A PYRAZOL CARBOXYLIC ACID DERIVATIVE
IL255391A0 (en) A process for the preparation of aryl and heteroaryl acetic acid derivatives
PL2646416T3 (pl) Ulepszony sposób wytwarzania 2-trifluorometylo-5-(1-podstawionych) allkilopirydyn
ZA201308884B (en) Production method of imidazole derivatives
IL221005A (en) Method for Synthesis of 5-Amino-1-Phenyl-3-Cyano-4-Trifluoromethyl Sulfinyl Phosphorus
EP2746284A4 (en) SALT AND POLYMORPH OF PYRAZOLOPYRIMIDINONE COMPOUND AND DRUG COMPOSITION, PREPARATION METHOD AND USE THEREOF
EP2598485A4 (en) NEW MONTELUKAST 4-HALOGENOBENZYLAMINE SALT AND PROCESS FOR PREPARING MONTELUKAST SODIUM SALT USING THE SAME
IL221258A0 (en) Method for producing cyanoalkenylcyclopropanecarboxylic acid salt